|Articles|October 28, 2015

Alison Morris on the Future of Screening for Distress

Alison Morris, Hematology/Oncology Nurse Practitioner, Stanford Health Care, discusses her hopes for the future of screening for emotional and physical distress.

Learn more about a study looking at emotional and physical distress.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!

Related Content

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

Suleika Jaouad, Reporting From the Front Lines of Leukemia

BySuleika Jaouad

December 12th 2025

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.

What Does Minimal Residual Disease Mean?

ByDr. Dickran Kazandjian

December 11th 2025

The Emmy-winning journalist and author delivered the keynote address at the inaugural Blood Cancer Heroes event.

Suleika Jaouad Celebrates Blood Cancer Heroes With CURE and Blood Cancer United

BySuleika Jaouad

December 10th 2025

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Breaking Down the Prostate Cancer Treatment Renaissance

ByDr. Kai Tsao

December 9th 2025

Dr. Robert Orlowski, chairman, Ad Interim; director of Myeloma; and professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

ByDr. Robert Orlowski

December 8th 2025

Alison Morris on the Future of Screening for Distress

Newsletter

Related Content

Suleika Jaouad, Reporting From the Front Lines of Leukemia

What Does Minimal Residual Disease Mean?

Suleika Jaouad Celebrates Blood Cancer Heroes With CURE and Blood Cancer United

Breaking Down the Prostate Cancer Treatment Renaissance

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

Trending on CURE

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

What Does Minimal Residual Disease Mean?

From Stage 4 to Survivor: Dan’s Pancreatic Cancer Journey

Radiation Plus Keytruda Before Surgery Boosts Immune Response in Breast Cancer